Relapses and disability accumulation in progressive multiple sclerosis

Neurology

Volumn 84, Issue 1, 2015, Pages 81-88

  Soldán, M Mateo Paz ^a   Novotna, Martina ^a,c   Zeid, Nuhad Abou ^d   Kale, Nilufer ^e   Tutuncu, Melih ^f   Crusan, Daniel J ^b   Atkinson, Elizabeth J ^b   Siva, Aksel ^f   Keegan, B Mark ^a   Pirko, Istvan ^a   Pittock, Sean J ^a   Lucchinetti, Claudia F ^a   Weinshenker, Brian G ^a   Rodriguez, Moses ^a   Kantarci, Orhun H ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic College of Medicine   (United States)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^d AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^e Bakirkoy State Hospital   (Turkey)

^f ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BOUT ONSET PROGRESSIVE MULTIPLE SCLEROSIS; CONTROLLED STUDY; DISABILITY; DISEASE ASSESSMENT; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PRIORITY JOURNAL; RELAPSE; SEX DIFFERENCE; SINGLE ATTACK PROGRESSIVE MULTIPLE SCLEROSIS; DISEASE COURSE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

IMMUNOLOGIC FACTOR;

ADULT; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925936255     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001094     Document Type: Article

References (40)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
2. Tutuncu M, Tang J, Zeid NA, et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 2013;19:188-198.
3. Kantarci O, Siva A, Eraksoy M, et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998; 51:765-772.
4. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281-300.
5. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study: I: clinical course and disability. Brain 1989;112: 133-146.
6. Kantarci OH, Weinshenker BG. Natural history of multiple sclerosis. Neurol Clin 2005;23:17-38, v.
7. Minderhoud JM, van der Hoeven JH, Prange AJ. Course and prognosis of chronic progressive multiple sclerosis: results of an epidemiological study. Acta Neurol Scand 1988;78:10-15.
8. Confavreux C, Vukusic S. Natural history of multiple sclerosis: A unifying concept. Brain 2006;129:606-616.
9. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: A geographically based study 9: observations on the progressive phase of the disease. Brain 2006;129:584-594.
10. Koch M, Mostert J, Heersema D, De Keyser J. Progression in multiple sclerosis: further evidence of an age dependent process. J Neurol Sci 2007;255:35-41.
11. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology 2011;77:1246-1252.
12. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
13. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-846.
14. Rodriguez M, Siva A, Ward J, Stolp-Smith K, O'Brien P, Kurland L. Impairment, disability, and handicap in multiple sclerosis: A population-based study in Olmsted County, Minnesota. Neurology 1994;44:28-33.
15. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: A 10-year follow-up study. Neurology 2004;62:51-59.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
17. Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999;122:625-639.
18. Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: A geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: A re-evaluation. Brain 1999;122:1941-1950.
19. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006;129:595-605.
20. Tremlett H, Zhao Y, Devonshire V. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol 2009;256:374-381.
21. Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol 2008;15:916-921.
22. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438.
23. Trojano M, Liguori M, Bosco Zimatore G, et al. Agerelated disability in multiple sclerosis. Ann Neurol 2002; 51:475-480.
24. Leray E, Yaouanq J, Le Page E, et al. Evidence for a twostage disability progression in multiple sclerosis. Brain 2010;133:1900-1913.
25. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-134.
26. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 2003;206:135-137.
27. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009;73:1616- 1623.
28. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: A geographically based study 10: relapses and long-term disability. Brain 2010;133: 1914-1929.
29. Fabian MT, Lublin F, Wolinsky J; The PROMISE Trial Study Group. Evaluation of progressive relapsing MS patients in the PROMISE Trial. Neurology 2011;76:A613.
30. Trojano M, Avolio C, Manzari C, et al.Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995;58:300-306.
31. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials. Neurology 2004;63:1779-1787.
32. SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-1504.
33. Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta- 1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:706-710.
34. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-687.
35. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001;57:1969-1975.
36. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: An exploratory, randomized, controlled trial. Neurology 2003;60:44-51.
37. Montalban X, Sastre-Garriga J, Tintore M, et al. A singlecenter, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 2009;15:1195- 1205.
38. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-1795.
39. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24.
40. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66:460-471.